Connect Biopharma Holdings Limited · NASDAQ:CNTB
Connect Biopharma — Jefferies Conference 2022
6 slides from Connect Biopharma's conference presentation, Jun 10, 2022
Slide 1: Jefferies Conference Presentation – June 10, 2022
Jefferies Conference Presentation – June 10, 2022 NASDAQ: CNTB DEVELOPING NEXT- GENERATION THERAPEUTICS FOR T CELL DRIVEN INFLAMMATORY DISEASES Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation regarding Connect Biopharma Holdings Limited ("Connect," "we," "us" or "our") has been prepared solely for informational purposes. Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data
Slide 3: Company Highlights
Company Highlights CBP-201: Interleukin-4-receptor alpha (IL4Rα) blocker (China Phase 2/3 Pivotal/Planning Global Phase 3) CBP-307: Sphingosine 1-phosphate-1 (S1P1) modulator CBP-174: Peripherally acting histamine-3 receptor (H3R) antagonist CBP-201: Potential first product approval for AD in China
Slide 4: Recent Accomplishments and Next Anticipated Milestones
Recent Accomplishments and Next Anticipated Milestones CBP-201 Confirmed trial design of ongoing Phase 2/3 pivotal AD study with China CDE; topline data on track for 1H ’23; potential approval in China as soon as 2025* Completed US FDA End of Phase 2 mtg for AD, enabling partnership discussions; pla
Slide 5: Robust Pipeline of Potentially Differentiated Therapies
Robust Pipeline of Potentially Differentiated Therapies Connect Biopharma has Global Development & Commercialization Rights to all Product Candidates INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3/Registrational NEXT ANTICIPATED MILESTONE CBP-201Antibody targeting IL-4Rα cytokine receptor (Th2 cell
Slide 6: Connect Biopharma
CORRECT BIOPHARMA.
Connect Biopharma Holdings — Jefferies Conference 2022 on 6ix